Navigation Links
Innocoll Submits SPA for Cogenzia(TM) Phase III Clinical Trials for the Adjuvant Treatment of Diabetic Foot Infections
Date:7/13/2010

ASHBURN, Va., July 13 /PRNewswire/ -- Innocoll, Inc. announced that its wholly-owned subsidiary, Innocoll Technologies Ltd., has submitted a Special Protocol Assessment (SPA) for a proposed phase 3 clinical trial to support the U.S. approval of Cogenzia™:  Innocoll's topical antibiotic therapy for the adjuvant treatment of infected diabetic foot ulcers.

The protocol was developed following an End of Phase 2 meeting with FDA where the results of Innocoll's phase 2 clinical studies were presented and discussed. In the planned phase 3 randomized, placebo-controlled, double-blind clinical trial, patients with a moderate or severe diabetic foot infection will be treated with Cogenzia on a daily basis as an adjunct to standard-of-care, which includes systemic antibiotic therapy administered by the oral or intravenous route. Patients will be treated for a maximum of 28 days and the primary endpoint will be the percentage of patients who are clinically cured of infection 10 days after discontinuation of all antibiotic therapy. The study design is based on a highly encouraging phase 2 trial where 100% of Cogenzia-treated patients who completed the study achieved clinical cure, which was statistically significantly superior to 70% of patients in the control group (P = 0.024). Patients in the Cogenzia group also had a significantly higher rate of baseline pathogen eradication and a reduced time to pathogen eradication (P < 0.001).

Dr. Michael Myers, Innocoll's President and CEO commented, "Building on the strength of the phase II data, we continue to make great strides in the development of our lead product, Cogenzia.   We are particularly encouraged by the fact that the product will be developed as adjuvant therapy for use in conjunction with systemic
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients
2. Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients
3. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
4. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
5. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
6. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
8. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
9. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
10. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
11. Advanced Life Sciences Submits Updated Special Protocol Assessment to FDA for Restanza in Community Acquired Bacterial Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)...  Astellas today announced topline results from the ... safety of intravenous (IV) and oral isavuconazole, commercially ... adults with candidemia and other invasive Candida ... the trial did not meet its primary endpoint ... patients at the end of IV therapy compared ...
(Date:7/29/2015)... 29, 2015  Unilife Corporation ("Unilife" or the "Company") ... manufacturer and supplier of injectable drug delivery systems, today ... provides the Company with flexibility and control to support ... signed an equity purchase agreement for up to $45 ... Chicago -based institutional investor, which provides ...
(Date:7/29/2015)... , July 29, 2015  According to data ... Services, the 2016 average monthly Medicare Part D premium ... far lower than was originally projected, the Pharmaceutical Care ... D program continues to be a bright spot in ... choices in each region and using cutting edge, cost-saving ...
Breaking Medicine Technology:Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 2Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 3Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 4Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 5Unilife Announces Multifaceted Financing Strategy 2Unilife Announces Multifaceted Financing Strategy 3Unilife Announces Multifaceted Financing Strategy 4Unilife Announces Multifaceted Financing Strategy 5
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... Ross ... (UCF) College of Medicine as Assistant Professor of Plastic Surgery. This is Dr. ... Clevens has worked closely with the university, developing a strong presence and a valuable ...
(Date:7/30/2015)... ... July 30, 2015 , ... Using the latest online digital technologies, happiness expert ... ways to prevent and manage major depression. , “Suicide is 100% preventable. The problem ... through the cracks and die needlessly everyday,” says Walker. “I’m out to end suicide. ...
(Date:7/30/2015)... ... July 30, 2015 , ... Between 2012 and 2014 HIV infection rates rose ... on June 17th. Those untreated heroin use disorders share their needles and spread ... dirty needles throughout the community. Ultimately Florida’s HIV infection rates have bolstered to 23 ...
(Date:7/30/2015)... ... July 30, 2015 , ... The American Association ... Rosenberg’s announcement of the reinstitution of National Prescription Drug Take-Back Days. The 10th ... 10:00 AM to 2:00 PM local time. On the 26th, the DEA, with ...
(Date:7/30/2015)... ... July 30, 2015 , ... InventHelp, a leading inventor service ... personal-care device that makes it easy to apply lotion or medication to a hard-to-reach ... assistance when applying lotion or medication to the back, and provides thorough coverage. The ...
Breaking Medicine News(10 mins):Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3Health News:Happiness Expert Develops Pioneering Online Tools for Sufferers of Major Depression, and Who may be Suicidal 2Health News:Happiness Expert Develops Pioneering Online Tools for Sufferers of Major Depression, and Who may be Suicidal 3Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 3Health News:AAPCC Supports National Prescription Drug Take-Back Day 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 3Health News:InventHelp® Client Patents “My Back Buddy” – Device Could Apply Lotion to Hard-to-Reach Areas Easily 2
... ROCHESTER, Minn. A new study led by researchers ... institutions has found that patients with non-Hodgkin,s lymphoma who ... diagnosis had poorer overall survival, compared to patients who ... after accounting for clinical and demographic factors, and also ...
... known by its brand name Celebrex, can help prevent the ... and small intestine of children with an inheritable genetic disease ... but devastating disease, polyps begin forming in patients as young ... or even thousands. The disease carries a 100-percent lifetime ...
... males tying the knot with younger females, study found , THURSDAY, ... nine years their junior could be upping their odds of dying ... younger guy raises a woman,s risk of death by 20 percent, ... Demography . , Not that marrying much older men is ...
... ... unveil the Center for Biotechnology Education on Thursday, May 13, at its fifth ... County campus, 9601 Medical Center Drive in Rockville. , ... (PRWEB) May 13, 2010 -- The Johns Hopkins University’s Zanvyl ...
... ... owners have been scratching their heads trying to understand the new EPA “Lead-Based Paint ... , ... 13, 2010 -- MT2, LLC of Arvada, CO is providing eco-protective green technology to ...
... The Wistar Institute offer a new explanation for the persistent ... why melanoma remains the deadliest form of skin cancer. The ... melanoma cells behave like both conventional tumor cells and cancer ... issue of the journal Cell thatcontrary to other ...
Cached Medicine News:Health News:Lifestyle factors significantly impact survival of non-Hodgkin's lymphoma patients, study finds 2Health News:Lifestyle factors significantly impact survival of non-Hodgkin's lymphoma patients, study finds 3Health News:Lifestyle factors significantly impact survival of non-Hodgkin's lymphoma patients, study finds 4Health News:Women Who Marry Younger Men May Die Earlier 2Health News:Johns Hopkins to Unveil Center for Biotechnology Education 2Health News:Johns Hopkins to Unveil Center for Biotechnology Education 3Health News:Contractors Discover Relief from New EPA LBP RRP Rule 2Health News:Contractors Discover Relief from New EPA LBP RRP Rule 3Health News:Wistar scientists explain the persistence of melanoma through 'dynamic stemness' 2Health News:Wistar scientists explain the persistence of melanoma through 'dynamic stemness' 3
An environmentally-safe, CN-free lytic reagent designed for use on the Abbott CELL-DYN® 1800 three-part differential hematology analyzer....
... Retics is a 5-part differential control that ... Abbott CELL-DYN 3200, 3500, 3700 and 4000 ... nucleated red blood cells that can be ... The assay contains automated and manual reticulocyte ...
... hematology control for the Abbott CELL-DYN 3000, ... for the five-part white cell differential, as ... CELL-DYN 1600 and 1700. Open-vial stability is ... days. Para 12 Plus is packaged in ...
The technology in the LATITUDE system allows your doctor to get the same data from your device whether you are at home or in your doctor's office. This information transfer happens automatically....
Medicine Products: